MétaCan
Menu
← Back to cohort
Record W7117243092 · doi:10.1002/alz70856_101081

Slow wave sleep as a biomarker and therapeutic target for Alzheimer's disease

2025· article· en· W7117243092 on OpenAlexaff
Brianne A. Kent, Mayuko Arai

Bibliographic record

VenueAlzheimer s & Dementia · 2025
Typearticle
Languageen
FieldNeuroscience
TopicSleep and Wakefulness Research
Canadian institutionsSimon Fraser University
Fundersnot available
KeywordsBiomarkerDiseaseSleep (system call)Slow-wave sleepTherapeutic approach

Abstract

fetched live from OpenAlex

Abstract Background Sleep disturbances are prevalent among individuals diagnosed with Alzheimer's disease (AD), typically manifested as low levels of slow‐wave sleep (SWS; N3 stage). Restoring SWS has been proposed as an intervention to slow AD progression. Trazodone, an antidepressant with sleep‐promoting properties, is frequently prescribed off‐label to improve sleep. Notably, it is well‐tolerated in elderly individuals and has been shown to specifically enhance SWS. Given its potential benefits, trazodone has been proposed as an intervention for AD. However, research on its effects beyond its antidepressant properties remains limited. This study aimed to evaluate the effects of chronic trazodone administration in a mouse model of AD, marking the first assessment of its potential as a disease‐modifying therapeutic for AD. Method We have developed a translationally‐focused administration paradigm for trazodone in C57BL/6J mice and demonstrated that acute trazodone administration dose‐dependently enhances NREM sleep and increases delta power during NREM sleep. Using this validated protocol, we administered trazodone (60mg/kg) daily to APP NL‐F mice (up to 60 days) to evaluate its effects on EEG power spectra, behaviour/cognition, and neuropathology. Two age groups were selected to represent early (9 months) and intermediate (14 months) stages of neuropathology. Result Preliminary analysis revealed that trazodone consistently enhances slow oscillation and delta power during NREM sleep over a 60‐day treatment period ( p = 0.0040, comparing baseline with 1, 4, and 8 weeks of treatment in the 9‐month‐old cohort). Importantly, preliminary neuropathological analysis reveals that 60 days of trazodone treatment leads to lower levels of Aβ pathologies, particularly in male mice. Specifically, in male APP NL‐F mice treated with trazodone from 14 to 16 months of age, the treatment was associated with significantly lower amyloid plaques in the dorsal hippocampus (46 % lower, p = 0.0174) and fibrillary plaques in the parietal cortex (18% lower, p = 0.0495). Furthermore, trazodone treatment in the male mice showed a downward trend in insoluble Aβ 42 levels (40% lower, p = 0.0555). Touchscreen cognitive testing is ongoing in 13‐ to 14‐month‐old APP NL‐F mice. Conclusion Our research suggests that trazodone should be explored as a potential disease‐modifying therapeutic for AD.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Theoretical or conceptual · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: none
Teacher disagreement score0.001
Threshold uncertainty score0.004

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0010.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.065
GPT teacher head0.328
Teacher spread0.263 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designTheoretical or conceptual
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueAlzheimer s & Dementia→Same topicSleep and Wakefulness Research→French-language works237,207→